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ORIGINAL ARTICLE – MELANOMAS
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ABSTRACT
Background. The aim of this study was to asses quality of
life (QoL) after axillary or inguinal sentinel lymph node
biopsy (SLNB) with or without completion lymph node
dissection (CLND) in patients with cutaneous melanoma
by comparing patients to a norm group of the general
population and by comparing QoL between four patient
groups depending on surgical procedure and location, i.e.,
patients receiving an axillary or groin SLNB, or an axillary
or groin CLND.
Methods. Between 1995 and 2003, a total of 242 axillary
and inguinal SLNBs were performed. Of the 127 patients
eligible for the study, 116 patients participated (91%). QoL
was measured by the 30-item European Organization for
the Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30), the McGill Pain Ques-
tionnaire and the Groningen Activity Restriction Scale.
Results. Median age at diagnosis was 50 (range, 18–77)
years; median Breslow thickness 2.0 (range, 1–13) mm;
median follow-up 56 (range, 4–94) months. SLNB only
was performed in 89 patients (77%): 48 in the groin and 41
in the axilla. CLND was performed in 27 patients (23%):
13 in the axilla and 14 in the groin. More postoperative
complications (13 vs. 5; P \ 0.001) and lymphedema (10
vs. 8; P \ 0.001) occurred in the CLND group than in the
SLNB group. The total group of patients reported better
physical (P \ 0.001), role (P \ 0.001), emotional
(P \ 0.001), and social functioning (P = 0.049), global
QoL (P \ 0.001), and less fatigue (P \ 0.001) and pain
(P \ 0.001) than a German norm group. Analysis of vari-
ance revealed significant differences in role functioning
(P = 0.02) and tendencies toward physical problems
(P = 0.051) and fatigue (P = 0.051) between the four
groups. Post hoc Bonferroni tests showed that the axillary
CLND group had more problems than the axillary and
inguinal SLNB groups. Kruskal-Wallis tests showed that
the axillary CLND group reported most pain.
Conclusions. QoL in melanoma survivors after axillary or
inguinal SLNB with or without CLND was better than that
in a norm group. Patients who underwent CLND in the
axilla after SLNB reported most problems.
Cancer patients experience numerous problems in
physical, emotional, social, practical, and spiritual func-
tioning. Those who survive their disease reportedly
continue to experience physical and psychosocial problems,
such as functional impairment; worries about recurrence,
second malignancies, or late effects of treatment; and
employment, financial, or insurance problems.1,2 However,
comparable or even better quality of life (QoL) has been
found in cancer survivors, as well as in long-term melanoma
survivors treated with isolated limb perfusion.3–6
Sentinel lymph node biopsy (SLNB) was developed by
Morton et al. in the 1990s to stage patients with clinical stage
I or II cutaneous melanoma.7 Over the years, it has proved to
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be a reliable staging method.8 Recently, the results of the first
multicenter selective lymphadenectomy trial (MSLT I) have
been published. The third interim analysis showed that
SLNB led to improved disease-free survival, but not to
improved survival.9 If SLNB is tumor positive, completion
lymph node dissection (CLND) is recommended. At present,
the MSLT II is investigating whether CLND may be omitted
in some patients with a tumor-positive SLNB.10
Various studies on breast cancer patients showed that
axillary SLNB led to less short-term and long-term mor-
bidity than completion axillary lymph node dissection
(ALND).11–14 Studies on QoL in breast cancer patients did
not detect any difference between patients who underwent
SLNB alone and patients who underwent SLNB and
ALND, whereas other studies showed that ALND was
associated with impaired QoL.15–19
In melanoma patients, complication rates after SLNB
(such as postoperative bleeding, infection, and lymphe-
dema) varied between 4.6 and 10.1%.8,20,21 Recent studies
have reported that morbidity after SLNB alone in mela-
noma patients was lower than that after SLNB followed by
CLND.20,22,23 In particular, the groin dissections after
SLNB were associated with more complications than
SLNB alone.23 A recent study found a negative correlation
between complications and QoL in breast cancer patients.16
To our knowledge, QoL studies in melanoma patients
after SLNB in the axilla or the groin, whether in combination
with CLND or not, have not been carried out. In the absence
of data from the literature, we first hypothesized that QoL in
stage I–II melanoma patients after SLNB would be the same
as that in the normal population. These patients have a rel-
atively favorable prognosis. However, melanoma patients
who underwent a lymph node dissection, in particular in the
groin, experience increased morbidity. Therefore, we also
hypothesized that patients with inguinal CLND would have
more QoL-related problems than patients with SLNB alone
and patients with an axillary CLND.
PATIENTS AND METHODS
Patient Population
In the period 1995–2003, a total of 242 patients under-
went inguinal and/or axillary SLNB at the University
Medical Center Groningen as a staging procedure for stage
I/II cutaneous melanoma ([1.0 mm). We excluded 46
patients who had died and 69 patients for one of the fol-
lowing reasons: bilateral axillary or inguinal SLNBs,
follow-up in a different area as a result of moving house,
preexisting functional limitations and/or previous surgery
to the relevant extremities, preexisting volume discrepan-
cies in the relevant extremities (e.g., status after stroke),
severe comorbidity such as dementia or disseminated dis-
ease, patients undergoing palliative therapy, and patients
who were receiving treatment for local or locoregional
recurrence at the time of the study.
Therefore, 127 patients were suitable candidates to take
part in this study. They were approached by telephone by
the research physician. Information about the study was
given verbally and they were invited to participate. At their
next outpatient follow-up visit, 116 patients (response rate
91%) provided written informed consent. These patients
underwent physical examination and were asked to fill in
the questionnaire at home and return it to us in the self-
addressed, stamped envelope provided. All the patients
returned the questionnaire. The internal review board of the
hospital approved the study.
SLNB Technique
Patients were admitted to the hospital to undergo the
SLNB, reexcision of scar tissue, and possible CLND. The
SLNB procedure has been described in detail previously.24
Excision specimens were sent for routine histopathological
analysis with hematoxylin-eosin (HE) staining. Specific
immunohistochemical staining was performed on HE-
negative specimens for the protein S100 and the mela-
noma-related antigen HMB45. If histopathological
examination of the sentinel lymph node revealed metastatic
melanoma tissue, then all those patients received CLND.
ALND comprised level I–III axillary dissection with
preservation of the pectoralis minor muscle. In the case of a
tumor-positive SLNB in the groin, superficial and deep
groin lymph node dissections were performed, in which the
femoroinguinal lymph nodes and the lymph nodes along
the iliac artery and vein were excised, together with the
obturator lymph nodes. After superficial lymphadenec-
tomy, the sartorius muscle was freed from its attachment to
the anterior superior iliac spine, moved in a medial direc-
tion, and fixed to the ligament of Poupart. This technique
has been described extensively in the past.25 Since 2002,
patients with HE-negative and immunohistochemistry-
positive sentinel lymph nodes underwent superficial lym-
phadenectomy alone. If additional positive lymph nodes
were found in the resection specimen, deep groin dissection
(iliac and obturator nodal dissection) was performed.
Instruments
Demographic data (sex, age) and clinical data were
extracted from the medical files. Complications in the first
30 days postoperatively comprised wound infection,
bleeding, seroma, and wound necrosis.
To determine the degree of lymphedema, the volumes of
the arms and/or legs were measured by an adapted version
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of the water displacement technique as described by Kissin
et al.26 Each arm or leg was submerged slowly in a large,
transparent water-filled cylinder until the level of the
axillary fold or inguinal fold was reached. The extremity
was then withdrawn from the cylinder and the displaced
water refilled in precise quantities and recorded as the
volume of the relevant arm or leg. Both healthy and
affected extremities were measured. Lymphedema in the
groin was classified according to the criteria formulated by
Baas (normal 0–6.5%, slight 6.5–20%, moderate 20–40%,
severe [40%). Lymphedema in the axilla was classified
according to the criteria formulated by Stillwell (normal 0–
10%, slight 10–20%, moderate 20–40%, marked 40–80%,
severe [80%).25,27
Quality of Life The 30-item European Organization for
the Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30) version 3.0 (Dutch
version) consists of five multi-item functional scales, three
symptom scales, a global health status/QoL scale, and six
single items.28 Transformation of the scores was performed
according to the instructions in the manual. Scores on all the
scales and single items could range from 0 to 100. Higher
scores on the functional and global health status QoL scales
reflect better functioning. On the symptom scales, higher
scores mean more symptoms or problems. A difference of
5–10 points on an EORTC QoL functional subscale is
considered to be a small clinically meaningful difference, a
difference of 10–20 points is considered to be a moderate
clinically meaningful difference, and a difference of [20
points is considered to be a large clinically meaningful
difference.29 In this study, the functional scales and the
symptom scales ‘‘fatigue’’ and ‘‘pain’’ were included in the
analyses.
To make comparisons with a normal population, use was
made of the reference data from the EORTC QLQ-C30
(n = 2,028).30 The only general population data available
is that of a German reference group. This norm population
was selected at random. Mean age of the population was
49.4 (standard deviation [SD] 17.2) years, and 56% were
women.
Pain Pain was measured with the Dutch version of the
McGill Pain Questionnaire.31 This questionnaire comprises
a number of groups of pain adjectives that within each
group reflect an ascending order of pain intensity. The
patient is asked to choose one word from each group that
best describes the pain. The adjectives are grouped onto
three categories that describe separate dimensions of pain:
sensory adjectives that describe how the pain feels,
affective adjectives that reflect emotions such as anxiety
and tension, and evaluative adjectives that express the
subjective intensity of the pain. Two scores are calculated
from the adjective list: the number of adjectives chosen
(McGill Pain Questionnaire, Number of Words Chosen
(MPQ-NWC)), and the intensity of these adjectives (sum of
the order of the words chosen; MPQ Pain Rating Index
(MPQ-PRI)). The higher the score, the more severe the
pain. In addition, a visual analog scale was used to measure
pain intensity (0 = no pain; 100 = unbearable pain).
Activities of Daily Living The Groningen Activity
Restriction Scale (GARS) measures restrictions in the
execution of 18 general activities of daily living.32,33 For
each of these items, the patient is asked whether he or she
can perform the activity independently and without
difficulty (score 1), independently but with some difficulty
(score 2), independently but with great difficulty (score 3),
or cannot perform the activity independently (only with the
help of others; score 4). Scores can therefore vary between
18 and 72 points. A higher score reflects more functional
restrictions.
Statistical Analysis
Descriptive statistics were used to analyze the patients.
The v2 and t-tests were used to compare the demographic
data and disease-related characteristics between the SLNB
tumor-negative group and the tumor-positive group.
Unpaired t-tests were computed to compare the patients to
the norm group. An analysis of variance (ANOVA) was
performed, followed by post hoc Bonferroni tests when the
ANOVA was statistically significant, to detect differences
between the following four groups: patients with tumor-
negative axillary SLNB (axillary SLNB), patients with
tumor-positive axillary SLNB followed by ALND (axillary
CLND), patients with tumor-negative inguinal SLNB (groin
SLNB), and patients with tumor-positive inguinal SLNB
followed by inguinal lymph node dissection (groin CLND).
In addition, the Kruskal-Wallis test was used to deal with the
small numbers. Differences with a P value of \0.05 were
considered to be statistically significant. SPSS version 14.0
(SPSS, Chicago, IL) was used to perform all the analyses.
RESULTS
Patients
The clinical and pathological data on the melanoma
patients are summarized in Table 1. Approximately one-
third of the respondents were men, median age in the total
group at the time of diagnosis was 50 (range, 18–77) years,
median Breslow thickness was 2.0 (range, 1–13) mm, and
median follow-up was 56.8 (range, 4–94) months. In the
total group, 62 patients underwent inguinal SLNB (53%)
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and 54 axillary SLNB (47%). The mean number of sentinel
lymph nodes excised was 2 (SD = 0.8).
Histopathological examination showed that 27 patients
(23%) had metastases from the melanoma in the SLNB: 14 in
the groin (of whom 3 had a superficial groin dissection only
after the change in surgical decision making in 2002) and 13
in the axilla. These tumor-positive patients underwent
CLND. The percentages of men and women were the same in
TABLE 1 Demographic, clinical, and pathological data of respondents
Characteristic Axillary and groin
SLNB (N = 89)
Axillary and groin
CLND (N = 27)
Test value P
Sex, n (%)
Male 33 (37) 9 (33) v2 = 0.13 0.723
Female 56 (63) 18 (67)
Age
Mean (SD) 48 (14.1) 53 (10.5) t = 2.1 0.037
Median 50 50
Range 18–75 35–77
Location primary melanoma, n (%)
Arm 19 (21) 5 (19) v2 = 0.3 0.861
Trunk 25 (28) 9 (33)
Leg 45 (51) 13 (48)
Breslow thickness (mm)




Present 27 (30) 9 (33) v2 = .14a 0.705
Absent 61 (69) 17 (63)
Unknown 1 (1) 1 (4)
Histology, n (%)
Superficial spreading 51 (57) 14 (52) v2 = 0.076b 0.783
Nodular 32 (36) 10 (37)
Acrolentiginous 1 (1) 1 (4)
Unknown 5 (6) 2 (7)
Follow-up in months
Mean (SD) 54 (23.7) 48 (22.8) t = 1.1 0.279
Range 4–94 5–78
Location SLNB, n (%)
Groin 48 (54) 14 (52) v2 = 0.036 0.849
Axilla 41 (46) 13 (48)
Number of SLN excised
Mean (SD) 2.0 (0.8) 1.9 (1.0) t = -0.4 0.849
Range 1–5 1–4
Postoperative complications, n/N (%)
Groin 2/48 (4) 7/14 (50) v2 = 18.3 \0.001
Axilla 3/41 (7) 6/13 (46) v2 = 10.7 0.001
Slight lymphedema, n/N (%)
Groin 3/48 (6) 9/14 (64) v2 = 23.4 \0.001
Axilla 5/41 (12) 1/13 (8) v2 = 0.2 0.653
SLNB sentinel lymph node biopsy, CLND SLNB followed by completion lymph node dissection, SD standard deviation
a v2 calculated on ulceration present and absent. Missing values omitted
b v2 calculated on superficial spreading and nodular. Acrolentiginous and missing values omitted
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the SLNB tumor-positive and tumor-negative groups.
However, there were more women (50 of 62, 81%) than men
(12 of 62, 19%, P \ 0.001) in the inguinal SLNB group,
whereas the percentages of men (30 of 54, 56%) and women
(24 of 54, 44%) in the axillary SLNB group were similar
(P = 0.414). Patients in the tumor-positive group were sig-
nificantly older than those in the tumor-negative group.
ANOVA showed a significant effect of group on age
(F = 2.70, P = 0.049). Subsequent Bonferroni testing
showed that the patients in the inguinal tumor-positive group
were significantly older (mean = 57.5 years, SD = 11.3)
than the patients in the inguinal tumor-negative group
(mean = 46.3, SD = 13.9, Bonferroni P = 0.036). No
significant difference in age was found between the
axillary tumor-positive (mean = 49.1 years, SD = 7.9)
and axillary tumor-negative groups (mean = 50.2 years,
SD = 14.2).
As far as disease characteristics were concerned, no
differences were found between the tumor-positive and
tumor-negative groups, except for complications and
incidence of lymphedema. Postoperative complications,
such as wound infection, seroma, wound necrosis, or
bleeding, occurred in 18 patients (16%): 9 (17%) of 54 in
the axillary group and 9 (15%) of 62 in the inguinal
group. Complications were statistically significantly more
common in the tumor-positive group than in the tumor-
negative group.
A total of 18 (16%) of the 116 patients had lymphe-
dema: 12 (19%) of 62 in the inguinal group and 6 (11%) of
54 in the axillary group (NS). In all the cases, the lymph-
edema was classified as slight. In the inguinal group,
lymphedema was statistically significantly more often
prevalent in the tumor-positive group than in the tumor-
negative group. This did not apply to the axillary group. An
independent t-test showed no statistically significant dif-
ference in follow-up time between patients with or without
lymphedema.
QoL, Pain, and Activities of Daily Living
Mean scores of the 116 melanoma patients on the EO-
RTC QLQ-C30 subscales were statistically significantly
higher than those in a healthy norm population from Ger-
many. The only exception was cognitive functioning, for
which the scores were similar (Table 2). Differences
between the study group and the norm group in global QoL
and emotional functioning were moderately clinically
meaningful; in role functioning, they were small but clin-
ically meaningful. However, in physical, cognitive, and
social functioning, they were small and negligible. The
QoL scores of the three patients who received a superficial
groin dissection due to a change in surgical decision
making in 2002 fell within the range of the total group.
ANOVA showed a significant effect of group on role
functioning (P = 0.021) and tendencies toward physical
functioning problems (P = 0.051) and fatigue (P = 0.051,
Table 3). The post hoc Bonferroni test showed that the
axillary SLNB tumor-positive group had statistically sig-
nificantly poorer scores on role functioning than the two
tumor-negative groups (Table 3). With regard to the clinical
relevance of the differences found between groups, it
seemed that in the patients who underwent ALND after
SLNB, the scores on global QoL, physical functioning, and
social functioning were 5–10 points lower than those in the
two tumor-negative groups. In addition, the difference in
social functioning compared with the inguinal tumor-posi-
tive group was between 5 and 10 points. The difference in
role functioning between the axillary tumor-positive group
and the three other groups was between 10 and 20 points.
The nonparametric Kruskal-Wallis test confirmed the
significant differences in physical functioning (P = 0.01)
and in role functioning (P = 0.01), but not the difference
in fatigue. In addition, the Kruskal-Wallis test showed
significant differences in MPQ Pain Rating Index
(P = 0.019) and MPQ Number of Words Chosen
TABLE 2 Descriptives of the EORTC QLQ-C30 of melanoma patients and reference group,30 and comparison between groups
Subscales/symptoms Study group (n = 116),
mean (SD)





Global quality of life 86.8 (14.5) 70.8 (22.1) 16 11.2 \0.001
Physical functioning 93.6 (9.9) 90.1 (16.7) 3.5 3.5 \0.001
Role functioning 94.1 (13.5) 88.0 (22.9) 6.1 4.5 \0.001
Emotional functioning 90.1 (15.8) 78.7 (21.0) 11.4 7.4 \0.001
Cognitive functioning 92.5 (13.8) 91.2 (17.0) 1.3 0.97 0.332
Social functioning 93.8 (14.5) 91.0 (19.4) 2.8 2.0 0.049
Fatigue 10.9 (15.3) 17.1 (22.0) -4.1 \0.001
Pain 7.2 (14.6) 15.4 (24.4) -5.6 \0.001
EORTC QLQ-C30 European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30
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(P = 0.019) between the groups. The axillary tumor-
positive group seemed to have more functioning problems
and symptoms than the other groups.
The relationship between the time elapsed since diag-
nosis and QoL were not statistically significant (r varied
between 0.01 and 0.14).
In view of our findings that the tumor-positive and
tumor-negative groups differed in age, complications, and
lymphedema, combined with the fact that there were more
women than men in the inguinal group than in the axillary
group, we performed additional analyses to evaluate how
these variables affected the outcome measures. Men had
significantly higher mean scores on physical functioning
(t = 3.1, P = 0.003) and the GARS (t = -3.1, P =
0.003) and a significantly lower score on fatigue (t = -2.6,
P = 0.011) than the women. Age seemed to be negatively
but weakly correlated with physical functioning (r =
-0.29, P = 0.002) and was positively and moderately
correlated with the GARS (r = 0.32, P = 0.001). The
older the patient, the poorer the level of physical func-
tioning and execution of daily activities.
Unpaired t-tests did not show any statistically significant
difference in QoL, pain, and activities of daily living
between patients with and without postoperative compli-
cations and the patients with and without lymphedema.
TABLE 3 Descriptives of the four study groups on the EORTC QLQ-
C30, GARS, and MPQ-PRI and MPQ-NWC scales, and ANOVA
Outcomes Mean (SD) F P
Global quality of life
Groin SLNB 87.8 (14.2) 0.55 0.647
Groin CLND 86.3 (13.3)
Axillary SLNB 87.2 (14.9)
Axillary CLND 82.1 (16.6)
Physical functioning
Groin SLNB 94.4 (10.0) 2.68A 0.051
Groin CLND 91.4 (9.2)
Axillary SLNB 95.3 (9.2)
Axillary CLND 87.2 (10.7)
Role functioning
Groin SLNB 95.4 (11.4) 3.37B 0.021
Groin CLND 94.0 (12.4)
Axillary SLNB 95.9 (12.8)
Axillary CLND 83.3 (19.2)
Emotional functioning
Groin SLNB 90.2 (17.1) 0.15 0.930
Groin CLND 92.3 (13.3)
Axillary SLNB 89.0 (16.2)
Axillary CLND 90.4 (13.5)
Cognitive functioning
Groin SLNB 92.4 (15.4) 0.51 0.675
Groin CLND 92.9 (12.6)
Axillary SLNB 93.9 (11.0)
Axillary CLND 88.5 (17.2)
Social functioning
Groin SLNB 93.8 (15.6) 2.19 0.094
Groin CLND 91.7 (15.7)
Axillary SLNB 97.2 (8.3)
Axillary CLND 85.9 (21.3)
Fatigue
Groin SLNB 10.6 (14.8) 2.68C 0.051
Groin CLND 6.3 (9.5)
Axillary SLNB 9.5 (13.3)
Axillary CLND 21.4 (23.3)
Pain
Groin SLNB 6.9 (14.9) 2.38 0.073
Groin CLND 7.1 (12.6)
Axillary SLNB 4.5 (11.2)
Axillary CLND 16.7 (21.5)
GARS (18–72)
Groin SLNB 18.8 (1.9) 0.29 0.833
Groin CLND 18.9 (1.5)
Axillary SLNB 18.7 (1.9)
Axillary CLND 19.3 (1.7)
Pain (VAS, 0–100)
Groin SLNB 3.2 (8.0) 0.91 0.437
Groin CLND 4.3 (7.4)
TABLE 3 continued
Outcomes Mean (SD) F P
Axillary SLNB 3.4 (11.3)
Axillary CLND 8.0 (11.6)
MPQ-PRI (0–36)
Groin SLNB 1.8 (3.9) 2.03 0.113
Groin CLND 1.9 (3.0)
Axillary SLNB 1.2 (3.1)
Axillary CLND 4.1 (4.6)
MPQ-NWC (0–20)
Groin SLNB 1.3 (2.7) 2.37 0.074
Groin CLND 1.5 (2.5)
Axillary SLNB 0.9 (2.3)
Axillary CLND 3.2 (3.4)
EORTC QLQ-C30 European Organization for the Research and
Treatment of Cancer Quality of Life Questionnaire C30, GARS
Groningen Activity Restriction Scale,32,33 MPQ-PRI McGill Pain
Questionnaire Pain Rating Index,31 MPQ-NWC McGill Pain Ques-
tionnaire Number of Words Chosen,31 ANOVA analysis of variance,
SD standard deviation, SLNB sentinel lymph node biopsy, CLND
completion lymph node dissection, VAS visual analog scale
Groin SLNB: n = 48; groin CLND: n = 14; axillary SLNB: n = 41;
axillary CLND: n = 13.
Post hoc Bonferroni test: A = axillary CLND vs. axillary SLNB,
P = 0.058; B = axillary CLND vs. axillary SLNB, P = 0.018; axil-
lary CLND vs. groin SLNB, P = 0.024; C = axillary CLND vs.
axillary SLNB, P = 0.085; axillary CLND vs. groin CLND,
P = 0.063
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DISCUSSION
In this study, QoL in patients with melanoma who
underwent SLNB as a staging procedure, with or without
CLND, was better than that in a German norm population.
A possible explanation is that we investigated an exclusive
group of melanoma patients with a relatively favorable
prognosis who had (so far) survived their disease. In
addition, the absence of important relationships between
time and QoL indicates that patients, on the whole, func-
tion equally well, whether the diagnosis was relatively
recent or years earlier. Other studies have also shown that
QoL in cancer survivors was better than that in people who
had never had cancer.3–5 Another explanation for the high
QoL reported in this study might be a shift in how the
patients appreciated and estimated their health status, the
so-called response shift.34,35 Despite possible persistent
treatment-related symptoms, patients judged their QoL
relative to their own QoL while they were still undergoing
treatment, resulting in even higher scores than that of
people who had never been confronted with a life-threat-
ening illness.36
Even though the differences between the melanoma
patients and the norm group were statistically significant,
with the exception of cognitive functioning, if we look at
the clinical relevance of those differences, then only the
differences in global QoL and emotional functioning were
clinically meaningful.
It was striking that these melanoma patients reported
less fatigue than the norm group because fatigue is a
common and long-term complaint in cancer patients. An
explanation might be that most of this group of melanoma
patients had undergone a relatively small surgical inter-
vention, without adjuvant chemotherapy or radiotherapy. It
seemed that fatigue was highest in the group of patients
after SLNB followed by completion ALND.
Our results did not confirm the hypothesis that patients
in the CLND group, particularly those who had undergone
groin dissection, would have more problems with QoL than
those in the group with SLNB alone. Statistically signifi-
cant differences or tendencies toward more problems were
found in physical functioning, role functioning, fatigue,
and pain. In clinical terms, meaningful differences were
also present in global QoL and social functioning. How-
ever, it was not the patients with groin dissections (an
intervention that is known to be associated with compli-
cations) who reported the most problems, but the patients
who underwent ALND.25,37–41
Postoperative complications could not explain the
higher prevalence of problems in the axillary tumor-posi-
tive group. Complications did not occur more frequently in
the patients who underwent ALND than in the patients with
inguinal lymph node dissection, even though complications
were more common in the patients whose SLNB had been
followed by dissection.
An explanation for this result might lie in the demo-
graphic or disease-related variables analyzed in this study.
Sex could not explain the finding of more problems in the
axillary tumor-positive group. In agreement with the lit-
erature, women with a melanoma reported more problems
than men.30 However, the percentage of female patients in
the axillary tumor-positive and tumor-negative groups was
the same. In relation to age, we found that older patients
reported more problems with physical functioning and
daily activities. It should be borne in mind that the inguinal
tumor-positive group, and not the axillary tumor-positive
group, contained a higher proportion of older patients.
To our knowledge, this is the first study that compared
QoL between melanoma patients and a group of people
from the normal population and that mapped differences
between patients with and without axillary or inguinal
lymph node dissection after SLNB. It is important to note
that our group of melanoma patients did not have any
evidence of disease at the time of this study. Several of the
groups had small numbers, particularly the tumor-positive
SLNB groups. If the groups had been larger, the study
would have had more power, and more of the differences
may have been statistically significant. Furthermore, this
was a cross-sectional study with wide variation in follow-
up duration. However, the duration of follow-up did not
seem to be correlated with QoL.
It can be concluded that the procedure of SLNB in the
axilla or groin in patients with a melanoma did not have
any negative effects on QoL. Our patients even reported
better QoL than the norm population. Patients with CLND
in the axilla after axillary SLNB had more problems than
those who underwent SLNB alone in the axilla or groin.
The clinical relevance of the differences found in this study
varied from moderate to small. On the basis of the insights
gained from this study, physicians and nurses provide
better information to melanoma patients, in particular to
patients who will receive an ALND after tumor-positive
SLNB, on QoL consequences of staging and treatment,
thus allowing better informed decision making.
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